ISSN (Online): 1694-4674
Annals of Medicine and Medical Sciences Annals of Medicine and Medical Sciences
Submit Manuscript
  1. Home
  2. Volume 04 (2025), Version 10
  3. Correlation of Serum CA-125 Marker with Histopathological Findings in …
Original Article Open Access

Correlation of Serum CA-125 Marker with Histopathological Findings in Ovarian Tumors

, ,
Annals of Medicine and Medical Sciences Volume 04 (2025), Version 10 August 15, 2025 pp. 904 - 911
264 128
Download PDF
PDF XML
Abstract

Objective: To evaluate the correlation between serum CA-125 levels and histopathological findings in ovarian tumors. Design: Prospective descriptive study. Subjects/Patients: A total of 59 patients with radiologically diagnosed ovarian tumors, presenting between May 2023 and October 2024, were included. Methods: Serum CA-125 levels were measured pre-operatively, and histopathological examination was performed post-surgery. Data were analyzed to assess the association between CA-125 levels and tumor type. Results: Of the 59 cases, 42 (71.18%) were benign, 15 (25.42%) malignant, and 2 (3.38%) borderline. Mean CA-125 levels were significantly higher in malignant tumors (406.38 ± 372.43 U/mL) compared to benign (28.79 ± 22.16 U/mL). Malignancy was more common in postmenopausal women. CA-125 levels were highest in high-grade serous carcinoma (888.96 ± 92.93 U/mL). Elevated CA-125 (>35 U/mL) showed a sensitivity of 93.33%, specificity of 76.19%, and accuracy of 80.70% for malignancy prediction. Conclusion: Serum CA-125 is a valuable biomarker in distinguishing malignant from benign ovarian tumors, especially in postmenopausal women and surface epithelial tumors.

References
  1. National Cancer Registry Programme. (2020). Consolidated report of the population-based cancer registries: 2020. Indian Council of Medical Research.
  2. International Agency for Research on Cancer. (2020). Globocan 2020: Estimated cancer incidence, mortality and prevalence worldwide in 2020. World Health Organization. https://gco.iarc.fr/
  3. Robbins, S. L., Cotran, R. S., Kumar, V., Abbas, A. K., & Aster, J. C. (2015). Pathologic basis of disease. Saunders Elsevier.
  4. Das, M. K., & Ghimire, S. (2018). Histopathological study of ovarian lump and serum tumor marker Ca 125 estimation as a screening tool. Journal of Nobel Medical College, 7(1), 30-36. https://doi.org/10.3126/jonmc.v7i1.20844
  5. Morales-Vásquez, F., Pedernera, E., Reynaga-Obregón, J., López-Basave, H. N., Gómora, M. J., Carlón, E., Cárdenas, S., Silva-Ayala, R., Almaraz, M., & Méndez, C. (2016). High levels of pretreatment CA125 are associated with improved survival in high-grade serous ovarian carcinoma. Journal of Ovarian Research, 9, 41. https://doi.org/10.1186/s13048-016-0247-6
  6. Patil, R. K., Bhandari, B., Kittur, S. K., Haravi, R. M., S, A., & Jadhav, M. N. (2017). Histomorphological study of ovarian tumors: At a tertiary care centre. APALM, 4, A638-A645. https://doi.org/10.21276/APALM.1412
  7. Patel, N., Bavikar, R., & Ingale, Y. P. (2024). Histomorphologic analysis of ovarian tumors according to the new 2020 WHO classification of female genital tumors. Journal of Cancer Research and Therapeutics, 20, 966-971. https://doi.org/10.4103/jcrt.jcrt_2607_22
  8. Rao, P. S., Sharma, P., Mogra, N., & Talreja, K. (2020). Histopathological study of ovarian tumours in a tertiary healthcare centre of Southern Rajasthan. IJPO, 7, 561-566. https://doi.org/10.18231/j.ijpo.2020.112
  9. Bhagat, S., Majumdar, P., Bhattacharjee, P., & Raj, R. (2024). CA125 and ovarian neoplasm: Do they tally in the rally? Study in Eastern India. Research Journal of Medical Sciences (Res. J. Med. Sci.), 18, 343-346. https://doi.org/10.59218/makrjms.2024.4.343.346
  10. Agarwal, D., Kaur, S., Agarwal, R., & Gathwal, M. (2018). Histopathological analysis of neoplastic lesions of the ovary: A 5-year retrospective study at a tertiary health care centre. IJCMR, 5. https://doi.org/10.21276/ijcmr.2018.5.5.36
  11. Pant, H., Prakash, A., Khandelwal, R., & Pandey, S. (2019). Correlation of serum CA-125 with histopathological findings in ovarian tumors. JDPO, 4, 81-85. https://doi.org/10.18231/j.jdpo.2019.016
  12. Shintre, S. A., Survase, R. M., Patil, N. A., & Sayyed, R. (2017). Effectiveness of risk of malignancy index to differentiate benign from malignant ovarian masses: A cross- sectional study. International Journal of Health Sciences and Research, 7.
  13. Marachapu, J., & Vij, S. (2023). Histomorphological spectrum of ovarian lesions from a single institute. International Journal of Research in Medical Sciences, 11, 1141-1145. https://doi.org/10.18203/2320-6012.ijrms20230851
  14. K, A., Patil, A. G., A. M., & Devarmani, S. (2021). Histopathological spectrum of ovarian neoplasms and their clinicopathological correlation. International Journal of Health and Clinical Research, 4, 125-128.
  15. Habib, K. A., Jumaa, M. G., & Hussein, M. J. (2015). Determination of serum CA125 and evaluation of its efficiency as a screening tool for early detection of ovarian tumors. Baghdad Science Journal, 12.
  16. Verma, N., Tiwari, V., Sharma, S. P., Singh, P., Rathi, M., & Gupta, T. (2018). Clinico-pathological correlation of ovarian tumors and tumor-like lesions with the role of CA125 and HE4 as biomarkers for discrimination of benign and malignant ovarian tumors. International Journal of Research in Medical Sciences, 6, 2238.
  17. Neogi, S. S., & Srivastava, L. M. (2014). Elevated tumour marker CA125: Interpretations in clinical practice. Current Medicine Research and Practice, 4, 214-218. https://doi.org/10.1016/j.cmrp.2014.09.004
  18. Kayastha, S. (2009). Study of ovarian tumours in Nepal Medical College Teaching Hospital. Nepal Medical College Journal, 11, 200-202.
Author Resources